Psyence Biomedical (Nasdaq: PBM) is a biopharmaceutical company focused on nature-derived (non-synthetic) psilocybin and ibogaine therapeutics — a distinct, later-listed entity from the earlier Psyence Group. Its lead candidate, NPX-5, is a 25 mg nature-derived psilocybin therapy for adjustment disorder in cancer patients receiving palliative care. In 2026 the company expanded its Australian clinical-site network and dosed the first patient in a multi-site Phase 2b trial of NPX-5.
Psyence Biomedical News 44 articles
- Psyence doses first patient in Phase 2b psilocybin trial for cancer-related adjustment disorder
- Psyence expands Australian clinical site network to five sites
- Psyence Biomedical's 1-for-6.25 share consolidation takes effect
- Psyence Biomedical and partner PsyLabs report high-purity, GMP-aligned ibogaine extract
- Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
- Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
- Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
- Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
- Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
- Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
- Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
- Psyence Biomed Announces $2.0 Million Private Placement
- Psyence Biomedical : Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial Form 6K
- Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
- Psyence Group Enters Into Agreements With Its NASDAQ-Listed Associate, Psyence Biomedical, To Settle Outstanding Obligations
- Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
- Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
- Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq Form 6 K
- Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
- Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
- Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
- Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
- Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
- Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
- Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
- Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
- Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
- Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
- Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)
- Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
- Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
- Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
- Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
- Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
- Psyence Biomedical Ltd. Provides Update on Upcoming Phase IIb Trial
- Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
- Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Showing the 40 most recent of 44 articles.